<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019890</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067277</org_study_id>
    <secondary_id>NCI-99-C-0132</secondary_id>
    <nct_id>NCT00019890</nct_id>
    <nct_alias>NCT00001825</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma</brief_title>
  <official_title>Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed With MART-1 and gp100 Melanoma Antigens in Patients With High Risk Stage III or Completely Resected Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating&#xD;
      patients who have high-risk stage III or completely resected metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the immunologic activity of CD34+ derived and peripheral monocyte derived&#xD;
      dendritic cells pulsed with MART-1 and gp100 melanoma antigens in patients with high risk&#xD;
      stage III or completely resected metastatic melanoma.&#xD;
&#xD;
      PROTOCOL OUTLINE: This is a randomized study. Patients receive dendritic cells derived either&#xD;
      from peripheral monocytes or CD34+ cells.&#xD;
&#xD;
      Dendritic cells are pulsed with MART-1 and gp100 immunodominant HLA-A201 peptides prior to&#xD;
      infusion, and are administered intralymphatically in the lower extremities for the first 2&#xD;
      courses. Beginning with courses 3 and 4, dendritic cells are administered subcutaneously in&#xD;
      the anterior thigh. Dendritic cells are not administered to any extremity that has undergone&#xD;
      lymph node dissection.&#xD;
&#xD;
      Patients are randomized to the following treatment arms:&#xD;
&#xD;
      Arm I: Patients undergo leukapheresis to obtain peripheral monocytes. Patients receive&#xD;
      dendritic cells derived from peripheral mononuclear cells pulsed with MART-1 and gp100 every&#xD;
      4 weeks for up to 4 courses.&#xD;
&#xD;
      Arm II: Patients receive 5 daily subcutaneous injections of filgrastim (G-CSF) followed by&#xD;
      leukapheresis on days 5 and/or 6. Patients receive dendritic cells derived from CD34+ cells&#xD;
      pulsed with MART-1 and gp100 every 4 weeks for up to 4 courses.&#xD;
&#xD;
      Patients are followed at 4 to 6 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL:&#xD;
&#xD;
      A maximum of 28 patients (14 per treatment arm) will be accrued for this study within 7&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">March 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Stage IV Melanoma</condition>
  <condition>Stage III Melanoma</condition>
  <condition>Recurrent Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dendritic cell-gp100-MART-1 antigen vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics-- High risk stage III melanoma (greater than 3 lymph nodes&#xD;
        positive) OR completely resected metastatic melanoma within 6 months of surgery Disease&#xD;
        free by CT scan HLA-A201 positive --Prior/Concurrent Therapy-- Biologic therapy: At least 4&#xD;
        weeks since prior biologic therapy No prior MART-1 or gp100 peptide immunization No&#xD;
        concurrent biologic therapy Chemotherapy: At least 4 weeks since prior chemotherapy No&#xD;
        concurrent chemotherapy Endocrine therapy: At least 4 weeks since prior endocrine therapy&#xD;
        No concurrent systemic steroid therapy Radiotherapy: At least 4 weeks since prior&#xD;
        radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics No concurrent&#xD;
        surgery --Patient Characteristics-- Age: 16 and over Performance status: ECOG 0-1 Life&#xD;
        expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least&#xD;
        90,000/mm3 No coagulation disorder Hepatic: Bilirubin no greater than 1.6 mg/dL AST or ALT&#xD;
        less than 3 times upper limit of normal Renal: Creatinine no greater than 2.0 mg/dL&#xD;
        Cardiovascular: No major cardiac disease Pulmonary: No major pulmonary disease Other: Not&#xD;
        pregnant or nursing Fertile patients must use effective contraception No active systemic&#xD;
        infection No autoimmune disorders HIV negative Hepatitis B surface antigen negative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Patrick Hwu</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <verification_date>June 2001</verification_date>
  <study_first_submitted>March 2, 2007</study_first_submitted>
  <study_first_submitted_qc>March 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2007</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>adult solid tumor</keyword>
  <keyword>body system/site cancer</keyword>
  <keyword>cancer</keyword>
  <keyword>melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>skin tumor</keyword>
  <keyword>solid tumor</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>stage, melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

